Cytek Biosciences disclosed preliminary, unaudited revenue figures for the fourth quarter and full year ended December 31, 2025. The company projects total revenue of $201 million for 2025, up from $200.5 million to $201.3 million in 2024, and expects fourth‑quarter revenue of $62 million, an 8 % increase over the same period in 2024 and a 19 % rise from the third quarter of 2025.
The revenue beat analyst consensus of $196.71 million for the full year, driven by robust demand for the company’s Full Spectrum Profiling (FSP) platform. Services and reagents continued to grow, while Asia‑Pacific instrument sales added momentum. A return to positive instrument revenue in the EMEA region helped lift the quarter’s top line and underscored a recovery in a key geographic market.
Management highlighted the “meaningful acceleration of growth” in Q4, noting that the mix shift toward higher‑margin services and reagents, combined with a rebound in instrument sales, contributed to the stronger-than‑expected results. The company’s CEO, Dr. Wenbin Jiang, emphasized that the company is well positioned to deliver sustainable growth and profitability in a large flow‑cytometry market.
Margin performance was not disclosed in the preliminary release, but the company’s guidance for 2026 will provide further insight into profitability expectations. The preliminary figures suggest that Cytek’s operational execution remains strong, with a focus on expanding its recurring revenue base and capitalizing on the growing demand for high‑resolution cell analysis technologies.
The announcement signals that Cytek’s core technology continues to resonate with customers, and the positive Q4 acceleration indicates that the company’s strategic initiatives—such as expanding services and reagents and strengthening its presence in Asia‑Pacific and EMEA—are bearing fruit. Investors will likely view the results as confirmation of Cyteks’ growth trajectory and its ability to convert demand into revenue.
The company will present audited financial results and 2026 guidance near the end of February 2026, providing a clearer view of its long‑term outlook. Until then, the preliminary figures offer a snapshot of Cytek’s current performance and the momentum it has built over the year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.